Clinical Guest Contributors

  1. 4 Hidden Gaps In Clinical Trial Preparation For Small Biotechs 7/28/2026

    Gaps are not always visible at the executive level, but their consequences are very real — affecting timelines, budgets, data quality, and ultimately the likelihood of regulatory success.

  2. ImvivaBio's Trial For Off-The-Shelf CAR-T Strategy For Aggressive Malignancies 7/28/2026

    ImvivaBio CMO Jan Davidson-Moncada, MD, Ph.D., discusses the company's Phase 1b/2 study for aggressive T-cell malignancies, explaining their unmet need, the rationale for an allogeneic approach, and how they plan to address immune rejection.

  3. Clinical Trial Per-Patient Cost Analytics For Procurement And Sponsor Strategy 7/27/2026

    With the help of Beroe Inc.'s Surya Ponnam, discover how per-patient cost (PPC) analytics is evolving into a core capability for balancing cost, quality, speed, and patient outcomes.

  4. Expanded Access And Rollover Design Help CytoDyn Reach High-Need Cancer Patients 7/24/2026

    CEO Jay Lalezari and CFO Robert E. Hoffman share how CytoDyn meet patient needs when they approach trial design for cancer trials.

  5. Why Protocol Complexity Is Slowing First Patient In — And How Small Sponsors Can Fix Start-Up Inefficiencies 7/23/2026

    Protocol complexity directly affects timelines, costs, and execution quality. Consultant Jessica Cordes explains why this challenge requires sponsors to change their approach to protocol design, feasibility, and start-up.

  6. Delays At The Handoff: Where Breakdowns Occur Among The Sponsor, CRO, And Site 7/23/2026

    Consultant Jason C. Bork identifies 10 of the most common points at which a trial can break down before and after patient recruitment.

  7. Pharma R&D Pipeline Productivity: Three Ways To Enhance Bandwidth And Efficiency 7/22/2026

    PA Consulting's Naveed Panjwani explores how to improve pipeline productivity via resource utilization, tech-enabled operations, and execution discipline.

  8. The U.S. Clinical Trial Recruiting Pipeline Report – June 2026 7/22/2026

    This WhichTrial report breaks down which drug trials are growing the most and the least, drugs that are no longer being studied, and new drugs to the clinic from May 1 to June 30, 2026.

  9. Reduce Friction And Save Time: Revamp Site Training To Focus On Value Over Volume 7/21/2026

    TransCelerate BioPharma members Ashlin Dunne, Anne Marie Inglis, and Ann Katrine Miranda assess the state of site training, examine how training affects trial execution, and discuss a better path forward.

  10. The Cost And ROI Of Agentic AI In Clinical Trials: What Sponsors And CROs Need To Know 7/21/2026

    Beroe Inc. analyst T.G. Prasanna discusses agentic AI for clinical research and how it must be evaluated as a regulated operating cost transformation, with platform, orchestration, compliance, validation, and oversight costs modeled together.